Processa Pharmaceuticals, Inc. (PCSA)
1.76
-0.08
(-4.35%)
USD |
NASDAQ |
Sep 29, 16:00
1.77
+0.01
(+0.57%)
After-Hours: 20:00
Processa Pharmaceuticals Enterprise Value : 4.720M for Sept. 29, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 29, 2026 | 4.720M |
| September 28, 2026 | 4.944M |
| September 25, 2026 | 4.944M |
| September 24, 2026 | 4.972M |
| September 23, 2026 | 5.083M |
| September 22, 2026 | 5.055M |
| September 21, 2026 | 4.944M |
| September 18, 2026 | 5.279M |
| September 17, 2026 | 5.111M |
| September 16, 2026 | 4.972M |
| September 15, 2026 | 5.270M |
| September 14, 2026 | 5.055M |
| September 11, 2026 | 5.614M |
| September 10, 2026 | 4.972M |
| September 09, 2026 | 5.363M |
| September 08, 2026 | 5.837M |
| September 04, 2026 | 5.558M |
| September 03, 2026 | 5.530M |
| September 02, 2026 | 5.670M |
| September 01, 2026 | 5.530M |
| August 31, 2026 | 5.530M |
| August 28, 2026 | 5.558M |
| August 27, 2026 | 5.698M |
| August 26, 2026 | 5.754M |
| August 25, 2026 | 5.893M |
| Date | Value |
|---|---|
| August 24, 2026 | 5.865M |
| August 21, 2026 | 5.614M |
| August 20, 2026 | 5.796M |
| August 19, 2026 | 5.810M |
| August 18, 2026 | 5.670M |
| August 17, 2026 | 5.754M |
| August 14, 2026 | 6.592M |
| August 13, 2026 | 6.787M |
| August 12, 2026 | 6.955M |
| August 11, 2026 | 7.150M |
| August 10, 2026 | 7.094M |
| August 07, 2026 | 6.983M |
| August 06, 2026 | 6.228M |
| August 05, 2026 | 5.921M |
| August 04, 2026 | 5.726M |
| August 03, 2026 | 5.754M |
| July 31, 2026 | 5.810M |
| July 30, 2026 | 5.502M |
| July 29, 2026 | 5.474M |
| July 28, 2026 | 8.324M |
| July 27, 2026 | 7.039M |
| July 24, 2026 | 7.066M |
| July 23, 2026 | 7.821M |
| July 22, 2026 | 6.899M |
| July 21, 2026 | 6.061M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.903B |
| Corcept Therapeutics, Inc. | 12.08B |
| Veru, Inc. | 20.54M |
| Johnson & Johnson | 672.65B |
| Eli Lilly & Co. | 1.161T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.266M |
| Total Expenses (Quarterly) | 3.266M |
| EPS Diluted (Quarterly) | -1.187 |
| Earnings Yield | -317.5% |
| Normalized Earnings Yield | -310.07 |